A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

This publication has 15 references indexed in Scilit:

• A current view of tamoxifen for the treatment and prevention of breast cancer
  British Journal of Pharmacology, 1993
• Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer
  European Journal Of Cancer, 1993
• Goserelin depot in the treatment of premenopausal advanced breast cancer
  European Journal Of Cancer, 1992
• LH-RH Agonists in the Treatment of Metastatic Breast Cancer: Ten Years’ Experience
  Published by Springer Nature ,1992
• The Depot GnRH Analogue Goserelin in the Treatment of Premenopausal Patients with Metastatic Breast Cancer -A 5-Year Experience and further Endocrine Therapies
  Oncology Research and Treatment, 1991
• Zoladex® plus tamoxifen versus zoladex® alone in pre- and peri-menopausal metastatic breast cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 1990
• Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer
  British Journal of Surgery, 1989
• A Reappraisal of Oophorectomy in Carcinoma of the Breast
  Annals of Surgery, 1987
• Assessment of response to therapy in advanced breast cancer
  Published by Elsevier ,1977
• ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1
  The Lancet, 1896